Soy Protein
1. Identity and Natural Source
Botanical and Chemical Identity
Soy protein is derived from the soybean, Glycine max (L.) Merr., a leguminous plant in the family Fabaceae. The common names include soybean, soya bean, and soya. Soybean protein flours, concentrates, and isolates are good sources of all indispensable amino acids (IAA), though some products can be marginally deficient in sulfur amino acids. Soy, a major dietary component for centuries, contains the largest concentration of isoflavones — a class of phytoestrogens — and a variety of health benefits are associated with its consumption, primarily because of the isoflavones genistein, daidzein, and glycitein, which have a potential protective effect against a number of chronic diseases.
Common Forms and Preparations
Soy protein is commercially available in three primary concentrated forms, each differing in protein content, processing, and bioactive compound retention:
- Soy Protein Flour (SPF): The least refined form, produced by grinding defatted soy flakes. Soy protein concentrate contains less starch, fiber, and antinutritional factors (ANFs) such as trypsin inhibitors than soy protein flour; several of these components are known to obstruct optimal protein digestion, leading to lower protein quality scores of flour compared to concentrate.
- Soy Protein Concentrate (SPC): Soy protein concentrate is traditionally made by aqueous alcohol extraction of defatted soy flakes; the resulting product has a protein content of approximately 70% (N × 6.25), with the remaining portion being mainly insoluble carbohydrates. Alternatively, soy protein concentrate can be made by an acid-leach method to retain isoflavones and other beneficial phytochemicals, and to prevent protein denaturation.
- Soy Protein Isolate (SPI): Soy protein isolate is produced by alkaline extraction of the defatted flour, followed by precipitation at acid pH. The result is a powder that is at least 90% protein by weight; SPI has the highest digestibility and consistently scores a PDCAAS of 1.0, and is the form most commonly found in protein powders, bars, and meat alternatives.
A critical distinction within soy protein isolate manufacture concerns solvent washing. Aqueous alcohol washing (typically 60–80% ethanol) removes phospholipids and saponins, producing a product with neutral flavor and improved dispersibility, but this step also strips some isoflavones. Non-alcohol-washed SPI retains higher isoflavone levels but carries a more pronounced "beany" note. This has direct implications for studies examining isoflavone-dependent versus protein-dependent biological effects. Protein isolates contain reduced levels of isoflavones (690–1096 µg per gram of protein) compared to soy flours as a result of aqueous processing during manufacture, while a concentrate made by aqueous alcohol extraction is very low in isoflavones (73 µg per gram of protein), because the isoflavones are especially soluble in aqueous alcohol and are thus largely removed during processing.
Beyond concentrated supplement forms, soy protein appears in the diet through traditional whole-food preparations including tofu, tempeh, edamame, soymilk (doujiang), miso, soy sauce, and natto. These whole-food matrices vary substantially in their isoflavone content, fermentation status, and fiber composition.
2. Traditional and Historical Use
Origin and Early Cultivation
Archaeological findings suggest that soy was being grown in China, Korea, and Japan as early as 5,500 years ago. Historical records suggest that soy was domesticated as a major food crop around 1,100 B.C., and soy plays an outsized role in human history, having served as the primary source of protein in Asia for millennia. Soybeans were considered one of the "Five Sacred Grains" of the Zhou Dynasty, offering an abundant, inexpensive, and easily digestible source of protein.
Spread Across Asia
The migration of the soybean from northeast China was gradual: by the first century A.D. it had spread to central and south China and Korea, and sometime after this date and before the arrival of Europeans in the 16th century, soybeans were sown in Japan and Southeast Asia. Soy foods have a long history of use in northeast Asia in particular, and each country has developed its own soy-based cuisine appealing to local preferences.
Cultural Roles and Traditional Preparations
The earliest recorded use of soybeans was in the production of fermented products, such as soy sauce and miso; soy played a vital role in traditional East Asian cuisine, particularly in Chinese, Japanese, and Korean cooking. Fermented preparations dominated the earliest recorded uses — a reflection of both food preservation traditions and the need to reduce antinutritional factors in raw soybeans.
Jiang (soybean paste), thought to have originated before the Chou dynasty (722–481 BC), is considered one of the oldest condiments known, originally developed as a way of preserving protein-rich foods to be used either as seasonings or preserves. By the early T'ang dynasty (618–906 AD), soybean jiang and soy sauce had begun to move out of China into adjoining countries; Buddhist priests played a key role in taking soybean jiang eastward into Korea and Japan.
Soy foods are an intrinsic part of shojin ryori, vegan food eaten by Buddhist monks in Japan and other Asian countries. The widespread adoption of soy-based foods in East Asia was deeply rooted in cultural and physiological factors: dairy farming was not a significant part of the region's agriculture, partly due to the high prevalence of lactose intolerance, and unlike in Europe, where animal milk became a staple, most East Asians lacked the lactase enzyme necessary to digest it properly. Soybeans thus became a foundational protein source in a region where animal protein was ecologically limited.
The soybean produces more protein (as in the form of soymilk) per unit area of land than any other conventional farm crop. Tofu, produced by coagulating soymilk, served in the Chinese diet as an analog to the role meat and dairy filled in other food cultures, providing a concentrated, versatile protein source across multiple social strata.
3. Key Constituents and Active Compounds
Protein Composition and Amino Acid Profile
The principal value of soy as a dietary supplement derives from its protein content and amino acid completeness. Soy protein's PDCAAS of 1.0 reflects two characteristics: it contains all nine essential amino acids in adequate quantities, and its digestibility is high (true fecal digestibility 91–95%). Protein quality, as determined by the PDCAAS method, is a measure of a protein's ability to provide adequate levels of essential amino acids for human needs; soy protein is recognized as a high-quality plant protein, but published PDCAAS values may vary based on the soy protein ingredient as well as the reproducibility and accuracy of testing methods.
Under the newer Digestible Indispensable Amino Acid Score (DIAAS) framework, which is considered more accurate than PDCAAS, scores vary by processing form. For all soy products combined, mean DIAAS was 84.5 ± 11.4 and mean PDCAAS was 85.6 ± 18.2. Soy protein concentrate showed a mean DIAAS of 87.7 ± 10.3 and a mean PDCAAS of 103.4 ± 1.9, compared to soy protein flour, which had a mean DIAAS of 77.2 ± 9.0 and a mean PDCAAS of 81.3 ± 16.6. Soy protein isolate has a PDCAAS near 1.0 but a lower DIAAS of approximately 0.92.
One limitation of soy protein relative to animal proteins is its relatively lower content of sulfur-containing amino acids. Soy protein lacks the essential amino acid methionine and might lose some cysteine and lysine in processing. Commercial manufacturing procedures for soy isolates result in products with lower levels of the sulfur-containing amino acids cysteine and methionine compared to soy concentrates; these are essential amino acids that are important nutritional factors in all soy products.
Isoflavones (Phytoestrogens)
The most important phytochemicals in soybeans are the phytoestrogens, mainly the isoflavones genistein, daidzein, and glycitein. These compounds are structurally similar to human estrogens and act as selective estrogen receptor modulators (SERMs). Found abundantly in soybeans, these compounds exhibit selective estrogen receptor modulator (SERM)-like activity, favoring ERβ over ERα, which underlies their tissue-specific effects.
Of the soy isoflavones, genistein and daidzein in particular have been studied, but recently equol — a derivative — has gained interest because it is more biologically potent. Equol is produced from daidzein by intestinal bacteria, and not all individuals have the gut microbiota capable of making this conversion, which is a significant source of interindividual variability in clinical study outcomes.
The provision of accurate data on the phytoestrogen/isoflavone content of different foods, soy protein isolates, and supplements has been hampered until recently by the availability of suitable validated analytical methods. Studies illustrate large variability in the isoflavone content of isolated soy proteins, reinforcing the need to accurately determine the isoflavone content of foods and dietary supplements.
Other Bioactive Constituents
Soybeans contain additional components, such as isoflavones, lecithins, saponins, and fiber, that may improve cardiovascular health through independent mechanisms. Saponins are amphiphilic glycosides that may reduce cholesterol absorption, while soy fiber — particularly soluble oligosaccharides such as stachyose and raffinose — modulates the gut microbiome. Soy lecithin (phosphatidylcholine) is a byproduct of oil extraction and is frequently encountered as a separate supplement ingredient. Protease inhibitors (e.g., Bowman-Birk inhibitor, Kunitz trypsin inhibitor) are present in raw soybeans and are substantially reduced by heat treatment during processing.
Mechanisms of Action
The biological actions of soy protein and its isoflavones operate through several documented pathways:
- Cholesterol and Lipid Metabolism: Both genistein and daidzein increase LDL-receptor mRNA levels by 3- to 6-fold, significantly increasing the binding, uptake, and degradation of LDL, suggesting enhanced reuptake of newly secreted apoB-containing lipoproteins contributes to a net decrease in apoB secretion; diets containing the soy-derived phytoestrogens genistein and daidzein decrease plasma cholesterol in humans and experimental animals. Cellular cholesterol synthesis was inhibited 41% by genistein and 18% by daidzein at 100 µM concentrations in vitro. These are in vitro findings at pharmacological concentrations, and the extent to which they translate to physiological doses in humans requires careful interpretation.
- Estrogenic / SERM Activity: Genistein and daidzein exhibit SERM-like activity favoring ERβ over ERα; in vitro, in silico, and in vivo studies demonstrate their ability to modulate estrogenic pathways, inhibit oxidative stress, and influence reproductive and neurological function.
- Cell Cycle, Apoptosis, and Angiogenesis: Soy isoflavone mechanisms include androgen- and estrogen-mediated pathways, regulation of the cell cycle and cell proliferation, apoptosis, angiogenesis, and metastasis, as well as antioxidant and anti-inflammatory effects and epigenetic activity.
- Antioxidant Effects: In addition to potentially antiatherogenic effects, dietary supplementation with soy-derived isoflavones has been shown to reduce the in vitro oxidation susceptibility of LDL.
- Thyroid Peroxidase Inhibition: Studies performed in vitro and in animal models suggest that isoflavones can inhibit the activity of thyroid peroxidase, which reduces triiodothyronine and thyroxine synthesis.
- CYP450 Modulation: Pharmacokinetic interactions between soy isoflavones and drugs occur through the inhibition or induction of drug-metabolizing cytochrome P450 enzymes such as CYP3A4, CYP2A1, and CYP2C9, or through the inhibition of drug transporters such as P-glycoprotein and breast cancer resistance protein.
4. Scientific Evidence by Health Area
4.1 Cardiovascular Health and Cholesterol
The relationship between soy protein and cardiovascular risk is the most studied and most regulatory-relevant area of soy protein research. In 1999, the U.S. FDA authorized a health claim for soy protein and reduced risk of coronary heart disease (CHD). The FDA authorized the use, on food labels, of health claims on the association between soy protein and reduced risk of coronary heart disease, concluding that soy protein included in a diet low in saturated fat and cholesterol may reduce the risk of CHD by lowering blood cholesterol levels. The daily dietary intake level of soy protein associated with reduced risk of coronary heart disease in that claim was 25 grams or more per day.
However, the FDA subsequently re-evaluated the evidence. On the basis of the totality of the evidence — consisting of studies conducted before the 1999 authorization and subsequent publications — the FDA concluded that significant scientific agreement has not been reached to support the health claim. In 2017, the FDA proposed to revoke the existing heart disease health claim.
A 2019 meta-analysis published in PMC, which analyzed the 46 studies the FDA reviewed, found that soy protein significantly reduced LDL cholesterol by approximately 3–4% in adults. However, methodological concerns remain substantial. An American Heart Association Science Advisory from the Nutrition Committee published in 2006 stated that the effect of soy protein is small relative to the dose needed to confer clinical benefit, and concluded that the evidence base does not confirm the clinical importance of soy protein. A separate meta-analysis of the same 46 studies showed significant heterogeneity for both total cholesterol (I²=74%) and LDL-cholesterol (I²=55%), which could not be explained by numerous factors including study design, baseline cholesterol levels, dose of soy protein, soy protein food source, comparator treatment, and other hypothesized moderating factors.
It was not clear from the AHRQ evidence report whether soy protein, or other components of soy products such as isoflavones, were responsible for lowering LDL cholesterol. A review summarizing evidence on the cardiovascular benefits of non-protein soy components in relation to CVD risk factors such as hypertension, hyperglycemia, inflammation, and obesity concluded that available evidence suggests non-protein soy constituents improve markers of cardiovascular health; however, additional carefully designed studies are required to independently elucidate these effects.
Evidence strength summary: Clinical trials consistently demonstrate a modest reduction in LDL-cholesterol (approximately 3–4%) with soy protein at doses of ≥25 g/day. However, there is significant heterogeneity across studies, the active component (protein vs. isoflavones vs. other constituents) remains uncertain, and the magnitude of effect is small relative to available pharmacological cholesterol-lowering therapies. The FDA's 2017 re-evaluation removed the health claim's scientific consensus designation.
4.2 Menopausal Symptoms
The AHRQ Evidence Report, commissioned by the NIH (NCCAM and Office of Dietary Supplements), summarized the current evidence on the health effects of soy and its isoflavones on menopausal symptoms, bone health, cancers, cardiovascular diseases, kidney diseases, and cognitive function.
There is some, albeit limited, evidence that soy isoflavone intake is associated with a modest reduction in menopausal hot flushes, although it is not clear whether these effects are due to soy isoflavones or other nutritional components present in soybeans, such as polyunsaturated fat. There is some evidence for the efficacy of soy preparations for perimenopausal symptoms; however, the heterogeneity of the studies performed to date means it is difficult to make a definitive statement.
The SERM-like property of isoflavones, particularly their preferential binding to ERβ, provides a plausible mechanism, but clinical results are inconsistent and depend substantially on whether the individual produces equol — a more potent daidzein metabolite — via gut bacteria. Personalized treatment strategies that consider genetic polymorphisms and gut microbiota composition — particularly equol production status — should be a focus of future research and clinical application.
Evidence strength summary: Preliminary to moderate for hot flash reduction; systematic reviews characterize the overall evidence as inconsistent, with heterogeneity in soy product form, isoflavone content, dose, and equol-producer status being major confounders. Current evidence does not support a definitive clinical recommendation.
4.3 Bone Health
In response to declining estrogen levels, women can lose substantial amounts of bone mass in the decade following menopause, which markedly increases their fracture risk. The structural similarity of soy isoflavones to estradiol prompted investigation of their potential to protect bone.
A number of animal studies have shown that soy protein and/or its isoflavones positively influence bone mineral density (BMD). Human clinical evidence is less conclusive. In terms of human studies, there are limited numbers of trials that have examined the effects of soy and its isoflavones on bone; some of these clinical trials are of short duration (3 to 6 months), making the findings questionable since periods less than one year may not be sufficient to detect clinically relevant changes in bone mass, and even the findings from the few clinical studies of one to two year duration are inconclusive. For example, Vitolins et al. reported that daily consumption of 25 g soy protein with 5, 42, or 58 mg isoflavones had no bone-preserving effects in peri- and post-menopausal women in a two-year study.
A 2016 randomized controlled trial (RCT) reported that soy protein with isoflavones may confer a beneficial effect on bone health, analogous to the mode of action of antiresorptive agents, albeit to a lesser magnitude. A 2022 systematic review with meta-analysis of 18 RCTs published in PMC examined the effects of soy isoflavones on lumbar spine, femoral neck, and total hip BMD in menopausal women, with different types of soy phytoestrogens used across those trials, including genistein extracts, soy isoflavone extracts, soy protein isolate, and foods containing diverse amounts of isoflavones.
Evidence strength summary: Animal data are supportive; human clinical evidence is mixed, with inconclusive results from longer-duration trials. Short study durations, varying isoflavone doses, and lack of consistency in bone outcome measures limit firm conclusions.
4.4 Skeletal Muscle and Athletic Performance
Soy protein isolate is widely used as a plant-based protein supplement for muscle maintenance and performance. A 2023 systematic review of 19 RCTs published in PMC found that soy protein (SP) was found to provide identical increases in lean mass compared to whey in some studies. The same review concluded that SP supplementation may be an effective alternative to whey in promoting optimal muscle mass and strength gains, at least in young athletic populations, utilizing a protein intake of ≥ 1.6 g/kg body weight/day.
One mechanism of potential difference between soy and whey involves leucine kinetics. A double-blind RCT involving recreationally active young men ingesting 45 g of carbohydrates and 20 g of whey or soy (acute supplementation) followed by concurrent exercise found that the whey group had substantially greater postprandial peak plasma leucine concentrations than the SP group, although no differences were observed in myofibrillar and mitochondrial protein synthesis within 360 min post-recovery.
When soy and whey are matched for leucine content, differences in lean mass outcomes are minimized. A 12-week RCT using a prospective, two-group parallel-arm, randomized, double-blind study design found that participants were randomized to receive 19 grams of whey protein isolate or 26 grams of soy protein isolate daily, amounts selected to match for leucine content. These data indicate that increases in lean mass and strength in untrained participants are comparable when strength training and supplementing with soy or whey matched for leucine.
In a crossover RCT of elite soccer players, ten well-trained male soccer players completed three speed-endurance training trials receiving whey protein, soy protein, or an isoenergetic placebo (maltodextrin) according to a randomized, double-blind, crossover, repeated-measures design, with protein supplementation individually adjusted to reach a total protein intake of 1.5 g/kg/day. Increasing daily protein intake to 1.5 g/kg through ingestion of either whey or soy protein supplements mitigated field performance deterioration during successive speed-endurance training sessions without affecting exercise-induced muscle damage and redox status markers.
Studies on SP and endurance performance suggested potential beneficial effects of SP supplementation (at doses of 10–53.3 g) on exercise performance, including improvements in high-intensity and high-speed running performance, enhancement of maximal cardiac output, delayed fatigue, improved isometric muscle strength, and improved endurance in recreational cyclists; however, studies determining the efficacy of soy protein on VO₂max provided conflicting results.
Soy protein appears to be an effective alternative to whey protein in promoting optimal muscle mass and strength gains, but the data are limited, and its amino acid content is lower than that of whey protein.
Evidence strength summary: Moderate, with caveats. Soy protein supports muscle protein synthesis and lean mass accretion during resistance training, particularly when total protein intake is sufficient and leucine content is matched to whey. Differences between soy and whey may be primarily driven by leucine content and digestibility rate differences, which can be partially compensated by consuming larger doses of soy protein isolate.
4.5 Cancer — Breast and Prostate
Soybeans contain several constituents able to modulate carcinogenesis; among them, genistein and other phytoestrogens attract great interest, as they exhibit a plethora of biological actions, including breast and prostate cancer chemopreventive activity. However, the clinical evidence base is considerably more limited than the experimental evidence.
For breast cancer, the picture is complex. Early preclinical laboratory studies raised concerns that low concentrations of soy isoflavones might stimulate the proliferation of estrogen receptor-positive breast cancer cells, particularly through ERα-mediated pathways. There is some, albeit limited, evidence that soy isoflavone intake is associated with decreased breast and prostate cancer risk, although it is not clear whether these effects are due to soy isoflavones or other nutritional components present in soybeans. Emerging evidence suggests lifelong consumption of soy-based foods may reduce cancer risk.
For prostate cancer, different mechanisms of action have already been studied for the different isoflavones in multiple conditions, such as breast, gastrointestinal, and urogenital cancers; many of these mechanisms could also be demonstrated in the prostate, both in vitro and in vivo. It is important to stress that most of the results in this area were obtained with in vitro studies, where it is generally believed that plant molecules such as isoflavones may have a more pronounced effect when applied directly to cell culture versus in vivo; there is also a difference in dosage, with smaller doses used on average in vitro, ranging from low concentrations (0.1–5 µM) to medium (10–50 µM) and higher (200 µM) concentrations.
Evidence strength summary: Largely preclinical (in vitro and animal). Epidemiological studies in Asian populations with high lifelong soy intake show lower rates of hormone-sensitive cancers, but these associations are subject to substantial confounding. Translating these findings to supplemental use in Western populations is not supported by robust clinical trial data. The biphasic effects of genistein on ER-positive breast cancer cells at varying doses add complexity to any risk-benefit assessment.
4.6 Kidney Function
There is preliminary evidence that soy protein places less stress on the kidneys in comparison to other high-quality proteins, which over time could reduce the risk of developing renal disease in susceptible individuals such as those with diabetes; it has been proposed that replacing animal protein with soy protein leads to a decrease in hyperfiltration and glomerular hypertension, with resultant protection from diabetic nephropathy. However, a meta-analysis of 12 clinical studies involving 280 patients with chronic renal disease found that dietary soy protein did not affect glomerular filtration rate, although it significantly decreased serum creatinine, serum phosphorus, inflammation (assessed by CRP), and proteinuria.
No statistically significant changes in glomerular filtration rate were seen after 8 weeks of a soy protein diet in studies reviewed by the AHRQ evidence report.
Evidence strength summary: Preliminary. There is some evidence of reduced proteinuria and inflammation markers, but no consistent effect on glomerular filtration rate. More robust and longer-duration RCTs in well-characterized renal disease populations are needed.
4.7 Cognitive Function
Four studies examined the effects of soy on cognitive function of post-menopausal women and college students of both sexes in the AHRQ evidence report, with inconsistent findings. The putative mechanism involves estrogen-like activity in the brain, as estrogen is known to influence synaptic plasticity and neurotransmitter systems. Genistein is a polyphenolic molecule and the active form of the soy isoflavone genistin; it has both phytoestrogen and protein tyrosine kinase–inhibiting properties, and since tyrosine phosphorylation is involved in central nervous system regulation of neurotransmission, inhibition by genistein may be a novel strategy to directly modulate synaptic activity.
Evidence strength summary: Very preliminary; the number of clinical studies is small, populations studied are heterogeneous, and results are inconsistent. No clinical recommendation can be made on this basis.
4.8 Gastrointestinal Health
Our review suggests that there are consistent favourable changes in measures of GI health for some soy foods, such as fermented rather than unfermented soy milk, and for those individuals with a microbiome that can metabolise equol; however, as consumption of foods containing soy protein isolates and textured soy proteins increases, further clinical evidence is needed to understand whether these foods elicit similar or additional functional effects on GI health.
Evidence strength summary: Preliminary. Fermented soy products show more consistent GI benefit signals than isolates or textured proteins. Interindividual variability in microbiome composition — especially equol production status — is a critical moderating variable.
5. Body Systems Associated
- Cardiovascular system: LDL cholesterol reduction, blood pressure, endothelial function (via isoflavones).
- Musculoskeletal system: Muscle protein synthesis, lean mass accretion, bone mineral density (via isoflavone SERM activity).
- Endocrine system: Phytoestrogen/SERM activity at estrogen receptors; thyroid peroxidase inhibition by isoflavones.
- Renal system: Reduction of glomerular hyperfiltration, proteinuria, and serum phosphorus in chronic renal disease.
- Reproductive and menopausal health: Modulation of menopausal vasomotor symptoms via estrogenic pathways.
- Central nervous system: Putative estrogen-mediated neurotrophic and neuroprotective effects (primarily preclinical).
- Gastrointestinal system: Modulation of gut microbiome, equol production, and bowel function.
- Oncology (investigational): Chemopreventive properties of isoflavones via cell cycle regulation, apoptosis induction, and angiogenesis inhibition (primarily preclinical).
6. Dosage Forms and Reported Dosages
Soy protein is available in multiple supplement forms: powders (isolate or concentrate), capsules, meal replacement bars, fortified foods, and beverages. The following dosages are those reported in the cited clinical literature and regulatory documents, and are not recommendations:
- Cardiovascular health claim dosage (FDA): The daily dietary intake level of soy protein associated with reduced risk of coronary heart disease in the authorized health claim was 25 grams or more per day of soy protein.
- Bone health studies: One study used daily consumption of 25 g soy protein with 5, 42, or 58 mg isoflavones over two years; a separate RCT used 25 g protein from soy products as the intervention dose.
- Muscle mass / athletic performance: One 12-week RCT enrolled participants randomized to receive 26 grams of soy protein isolate daily (matched for leucine with 19 g whey isolate). Studies on endurance performance used SP supplementation doses ranging from 10 to 53.3 g per day. A systematic review found that SP supplementation may be effective utilizing a protein intake of ≥ 1.6 g/kg body weight/day.
- Soccer player performance: In one crossover trial, protein supplementation was individually adjusted to reach a total protein intake of 1.5 g/kg/day.
7. Safety Considerations and Drug Interactions
Thyroid Function
Evidence from animal and human studies suggests a link between soy consumption and goiter, an activity independent of estrogenicity; iodine deficiency greatly increases soy's antithyroid effects, whereas iodine supplementation is protective, and soy effects on the thyroid involve the critical relationship between iodine status and thyroid function. Studies performed both in vitro and in animal models suggest that the inhibition of thyroid peroxidase activity by isoflavones reduces triiodothyronine and thyroxine synthesis.
A clinical concern specific to soy protein supplementation involves levothyroxine absorption. Soy has been shown to interfere with the absorption of levothyroxine, a synthetic thyroid hormone used to treat hypothyroidism; this can cause inconsistent hormone levels and potentially make the medication less effective. It remains unclear whether soy may impair levothyroxine absorption, and further studies are needed to demonstrate the performance of novel levothyroxine formulations in patients on soy therapy. One RCT found a significant increase in TSH and reduction in free thyroxine after soy protein isolate supplementation, indicating a potentially detrimental effect on thyroid function.
Soy products may disrupt thyroid function, making it crucial for individuals on thyroid medications to monitor their soy intake.
Interaction with Warfarin
Soy protein food-drug interactions with warfarin may be more common than the literature suggests; a case report documented a 70-year-old white man stable on warfarin who developed subtherapeutic INR values after ingesting soy protein in the form of soy milk, and subtherapeutic INR values could not be explained by factors known to reduce the INR such as noncompliance, new medications, other alternative therapies, or increased consumption of vitamin K. Speculative mechanisms of soy milk–induced INR decline include changes in warfarin absorption or metabolism resulting from alterations in the P-glycoprotein efflux system or organic anion-transporting polypeptides.
Soy protein interactions with warfarin may be more common than the literature suggests, and further studies are needed to determine the exact mechanism. Soy is not contraindicated for patients receiving warfarin, but good communication about all dietary changes is needed to maintain INR stability.
Interaction with Tamoxifen
The interaction between soy isoflavones and tamoxifen is complex and debated, with varying evidence on drug efficacy. Genistein's agonist activity at ERα in some experimental contexts has raised the theoretical concern that high-dose isoflavone intake might interfere with the anti-estrogenic action of tamoxifen in ER-positive breast cancer treatment, though this has not been conclusively demonstrated in human clinical trials.
Endocrine Effects — Safety Review
Despite theoretical concerns about phytoestrogenic effects, a recent comprehensive review concluded that although it was postulated that high consumption of soy protein could potentially interfere with estrogenic signalling and result in negative health impacts, these concerns have not been supported by subsequent scientific studies; a recent review concluded that soy isoflavones do not interfere with the function of the endocrine system, and that soy isoflavone intake did not negatively affect thyroid function, breast or endometrial tissue, or oestrogen levels in women, or testosterone, oestrogen levels, sperm, or semen parameters in men.
Allergenicity
Soy is classified as one of the major food allergens by the FDA and is subject to mandatory labeling requirements in the United States. Soy allergy is more prevalent in infants and young children and frequently resolves with age. The major allergenic proteins in soy have been identified as Gly m 5 (β-conglycinin) and Gly m 6 (glycinin), both of which are major storage proteins found in all concentrated soy protein forms.
Antinutritional Factors
Raw soybeans contain protease inhibitors (trypsin inhibitors and Kunitz inhibitors), phytic acid, and lectins (hemagglutinins), all of which can impair nutrient absorption and digestion. Standard commercial processing — including heat treatment during the production of soy protein concentrate and isolate — substantially reduces or eliminates these antinutritional factors. Soy protein concentrate contains less starch, fiber, and antinutritional factors (ANFs) such as trypsin inhibitors than soy protein flour.
Overall Safety Profile
The AHRQ evidence-based review summarized the health effects of soy and its constituents on cardiovascular disease, menopausal symptoms, endocrine function, cancer, bone health, reproductive health, kidney function, cognitive function, and glucose metabolism, as well as safety issues and drug interactions associated with using soy. In the general population consuming soy protein at dietary levels or at the doses studied in clinical trials (typically 20–60 g/day), the overall safety record is favorable. The most clinically significant safety signals center on thyroid function in iodine-deficient individuals or those on levothyroxine, potential modulation of warfarin anticoagulation, and theoretical risks in persons with hormone-sensitive cancers using high-dose isoflavone supplements. Animal study data on behavioral effects at very high isoflavone doses — such as male cynomolgus monkeys fed soy protein isolate containing 1.88 mg isoflavones/g protein over 18 months demonstrating higher frequencies of intense aggressive and submissive behaviors — have not been replicated in well-controlled human trials and involved doses significantly exceeding typical supplemental ranges.
References
Go back